Form 4: Kalaris Therapeutics Chief Medical Officer Matthew Feinsod Reports Stock Option Grants
SEC Form 4 Filing
Matthew Feinsod, Chief Medical Officer of Kalaris Therapeutics, reports the acquisition of stock options.
Summary
- On April 10, 2025, Matthew Feinsod, the Chief Medical Officer of Kalaris Therapeutics, Inc., was granted two stock option awards.
- The first option is for 70,551 shares with a strike price of $7.31, vesting over four years with 25% vesting on December 31, 2025, and the remainder in equal monthly installments.
- The second option is for 101,000 shares with a strike price of $7.31, vesting over four years with 25% vesting on March 18, 2026, and the remainder in equal monthly installments.
- Both options expire on April 9, 2035, and are subject to continuous service.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future, but it's not a major event.
Positives
- The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment and performance.
Future Outlook
The document does not contain any specific forward-looking statements beyond the vesting schedules of the options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The vesting schedules are typical for such grants.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Vesting schedules of four years with a one-year cliff (25% vesting after one year) are common.
- Comparable companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- Shareholders may view the option grants as a positive sign, aligning management's interests with theirs.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/10/2025 | Date of stock option grants |
| 12/31/2025 | Vesting start date for the first option (25%) |
| 03/18/2026 | Vesting start date for the second option (25%) |
| 04/09/2035 | Expiration date for both stock options |
| 04/11/2025 | Date of Form 4 filing |
Keywords
stock options, Kalaris Therapeutics, Matthew Feinsod, Chief Medical Officer, Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.